DE202008018131U1 - Auf Knochen gezielte alkalische Phosphatase und Kits davon - Google Patents

Auf Knochen gezielte alkalische Phosphatase und Kits davon Download PDF

Info

Publication number
DE202008018131U1
DE202008018131U1 DE202008018131U DE202008018131U DE202008018131U1 DE 202008018131 U1 DE202008018131 U1 DE 202008018131U1 DE 202008018131 U DE202008018131 U DE 202008018131U DE 202008018131 U DE202008018131 U DE 202008018131U DE 202008018131 U1 DE202008018131 U1 DE 202008018131U1
Authority
DE
Germany
Prior art keywords
amino acid
alkaline phosphatase
sequence
residue
hpp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202008018131U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Enobia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enobia Pharma Inc filed Critical Enobia Pharma Inc
Publication of DE202008018131U1 publication Critical patent/DE202008018131U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Adornments (AREA)
  • Cereal-Derived Products (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE202008018131U 2007-05-11 2008-05-12 Auf Knochen gezielte alkalische Phosphatase und Kits davon Expired - Lifetime DE202008018131U1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
US917589P 2007-05-11

Publications (1)

Publication Number Publication Date
DE202008018131U1 true DE202008018131U1 (de) 2011-12-30

Family

ID=40001639

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202008018131U Expired - Lifetime DE202008018131U1 (de) 2007-05-11 2008-05-12 Auf Knochen gezielte alkalische Phosphatase und Kits davon

Country Status (25)

Country Link
US (1) US20100297119A1 (https=)
EP (3) EP2158319B1 (https=)
JP (1) JP5732603B2 (https=)
AT (1) ATE536413T1 (https=)
AU (1) AU2008250945B2 (https=)
BR (2) BR122019000505B1 (https=)
CA (1) CA2687001C (https=)
CY (1) CY2016005I1 (https=)
DE (1) DE202008018131U1 (https=)
DK (3) DK2158319T3 (https=)
ES (3) ES2471915T3 (https=)
FR (1) FR16C0007I2 (https=)
HR (1) HRP20140416T1 (https=)
HU (2) HUE031655T2 (https=)
IL (1) IL202057A0 (https=)
LT (1) LTC2368999I2 (https=)
LU (1) LU92976I2 (https=)
ME (1) ME01828B (https=)
NL (1) NL300798I2 (https=)
NO (1) NO2016002I1 (https=)
PL (3) PL2662448T3 (https=)
PT (3) PT2662448T (https=)
RS (1) RS53302B (https=)
SI (2) SI2368999T1 (https=)
WO (1) WO2008138131A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
CN101835802B (zh) 2007-06-01 2014-04-09 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
BR112012027765A2 (pt) 2010-04-30 2019-09-24 Enobia Pharma Inc. métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
WO2012016073A2 (en) 2010-07-28 2012-02-02 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
US9926544B2 (en) * 2014-01-24 2018-03-27 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins
US10822596B2 (en) * 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
LT3325011T (lt) 2015-07-24 2021-01-25 Gliknik Inc. Iš žmogaus baltymo fragmentų sulieti baltymai, siekiant sukurti tvarkingai multimerizuoto imunoglobulino fc kompozicijas su padidintu komplemento surišimu
JP6993961B2 (ja) * 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) * 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) * 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20240160671A (ko) 2016-04-01 2024-11-11 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
EP3464573B1 (en) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
WO2018004517A1 (en) 2016-06-27 2018-01-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
CN110177802A (zh) 2016-12-09 2019-08-27 格利克尼克股份有限公司 多聚化stradomer GL-2045的制造优化
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
WO2018164995A1 (en) * 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Glycoprotein manufacturing process
KR20190129058A (ko) * 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
CA3087569A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
ES2972119T3 (es) 2018-08-10 2024-06-11 Alexion Pharma Inc Cicatrización ósea en implantes utilizando fosfatasa alcalina
KR20220005560A (ko) 2019-05-06 2022-01-13 신세틱 바이오로직스, 인코퍼레이티드 알칼리성 포스페이트-기반 종양학 치료제
KR20220111693A (ko) * 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법
EP4084819A1 (en) 2020-01-03 2022-11-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Tnap locally administered for promoting periodontal health
AU2021338361A1 (en) * 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
US12083169B2 (en) * 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US20260027233A1 (en) * 2022-08-31 2026-01-29 University Of Utah Research Foundation Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
WO1995011984A2 (en) 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1995027071A2 (en) 1994-04-04 1995-10-12 Board Of Regents, The University Of Texas System An adenovirus supervector system
WO2001036620A2 (en) 1999-11-16 2001-05-25 Genzyme Corporation Vectors and transgenies with regulatory elements for gene delivery to the liver
US6905689B2 (en) 2002-07-22 2005-06-14 Roche Diagnostics Operations, Inc. Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
WO2005103263A1 (en) 2004-04-21 2005-11-03 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
WO2006002203A2 (en) 2004-06-23 2006-01-05 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
WO2006060641A2 (en) 2004-12-01 2006-06-08 Genzyme Corporation Methods for targeted delivery of genetic material to the liver
US7179903B2 (en) 2001-05-14 2007-02-20 Cell Genesys, Inc Liver specific transcriptional enhancer
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
WO1995011984A2 (en) 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1995027071A2 (en) 1994-04-04 1995-10-12 Board Of Regents, The University Of Texas System An adenovirus supervector system
WO2001036620A2 (en) 1999-11-16 2001-05-25 Genzyme Corporation Vectors and transgenies with regulatory elements for gene delivery to the liver
US7179903B2 (en) 2001-05-14 2007-02-20 Cell Genesys, Inc Liver specific transcriptional enhancer
US6905689B2 (en) 2002-07-22 2005-06-14 Roche Diagnostics Operations, Inc. Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
WO2005103263A1 (en) 2004-04-21 2005-11-03 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
WO2006002203A2 (en) 2004-06-23 2006-01-05 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
WO2006060641A2 (en) 2004-12-01 2006-06-08 Genzyme Corporation Methods for targeted delivery of genetic material to the liver
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia

Non-Patent Citations (82)

* Cited by examiner, † Cited by third party
Title
"Molecular cloning, a laboratory manual, zweite Auflage aus 1989 von Sambrook et al.
Ali et al. 1970
Ali, S. Y., Sajdera, S.W. & Anderson, H.C. Isolation and characterization of calcifying matrix vesicles from epiphyseal cartilage. Proc Natl Acad Sci U S A 67, 1513-20 (1970)
Anderson & Reynolds 1973
Anderson 1997
Anderson 2004
Anderson et al. 2004
Anderson et al. 2005a
Anderson et al. 2005b
Anderson HC & Reynolds JJ 1973 Pyrophosphate stimulation of calcium uptake into cultured embryonic bones. Fine structure of matrix vesicles and their role in calcification. Developmental Biology 34 211-227
Anderson HC, Garimella R & Tague SE 2005a The role of matrix vesicles in growth plate development and biomineralization. Frontiers in Bioscience 10 822-837
Anderson HC, Harmey D, Camacho NP, Garimella R, Sipe JB, Tague S, Bi XH, Johnson K, Terkeltaub R & Millan JL 2005b Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleoticle pyrophosphatase phosphodiesterase 1 double-deficient mice. American Journal of Pathology 166 1711-1720
Anderson HC, Sipe JB, Hessle L, Dhamyamraju R, Atti E, Camacho NP & Millan JL 2004 Impaired Calcification Around Matrix Vesicles of Growth Plate and Bone in Alkaline Phosphatase-Deficient Mice. American Journal of Pathology 164 841-847
Anderson, HC, Hsu, H.H., Morris, D.C., Fedde, K.N. & Whyte, M.P. 1997 Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals. Am J Pathol 151 1555-61
Bernard 1978
Bernard, G.W. 1978 Ultrastructural localization of alkaline phosphatase in initial intramembranous osteogenesis. Clin Orthop, 218-25
Di Mauro et al. 2002
Di Mauro et al., 2002
Di Mauro S, Manes T. Hessle L, Kozlenkov A, Pizauro JM, Hoylaerts MF & Millan JL 2002 Kinetic characterization of hypophosphatasia mutations with physiological substrates. Journal of Bone and Mineral Research 17 1383-1391
Farley & Magnusson, 2005
Farley JR & Magnusson P 2005 Effects of Tunicamycin, Mannosamine, and Other Inhibitors of Glycoprotein Processing on Skeletal Alkaline Phosphatase in Human Osteoblast-Like Cells. Calcified Tissue International 76 63-74
Fedde et al. 1999
Fedde et al., 1999
Fedde KN, Blair L, Silverstein J, Coburn SP, Ryan LM, Weinstein RS, Waymire K, Narisawa S, Millan JL, MacGregor GR & Whyte MP 1999 Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. Journal of Bone and Mineral Research 14 2015-2026
Greenberg, 1993
Greenberg, C.R. et al. 1993 A homoallelic Gly317 → Asp mutation in ALPL causes the perinatal (lethal) form of hypophosphatasia in Canadian mennonites. Genomics 17, 215-7
Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R & Millan JL 2004 Concerted Regulation of Inorganic Pyrophosphate and Osteopontin by Akp2, Enpp1, and Ank: An Integrated Model of the Pathogenesis of Mineralization Disorders. American Journal of Pathology 164 1199-1209
Harmey D, Johnson KA, Zelken J, Camacho NP, Hoylaerts MF, Noda M, Terkeltaub R & Millan IL 2006 Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. Journal of Bone and Mineral Research 21 1377-1386
Harmey et al. 2004
Harmey et al. 2006
Hawrylak K & Stinson RA 1988 The solubilization of tetrameric alkaline phosphatase from human liver and its conversion into various forms by phosphatidylinositol phospholipase C or proteolysis. Journal of Biological Chemistry 263 14368-14373
Henthorn et al 1992a
Henthorn et al 1992b
Henthorn, P.S. & Whyte, M.P. 1992b Missense mutations of the tissuenonspecific alkaline phosphatase gene in hypophosphatasia. Clin Chem 38, 2501-5
Henthorn, P.S., Raducha, M., Fedde, K.N., Lafferty, M.A. & Whyte, M.P. 1992a Different missense mutations at the tissue-nonspecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia. Proc Natl Acad Sci U S A 89, 9924-8
Hessle et al. 2002
Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R & Millan JL 2002 Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proceedings of the National Academy of Sciences of the United States of America 99 9445-9449
Ikezawa 2002
Ikezawa H 2002 Glycosylphosphatidylinositol(GPI)-Anchored Proteins. Biol Pharm. Bull. 25(4) 409-417
Jansonius JN 1998 Structure, evolution and action of vitamin B6-dependent enzymes. Current Opinian in Structural Biology 8 759-769
Jansonius, 1998
Johnson K, Moffa A, Chef Y, Pritzker K, Goding J & Terkeltaub R 1999 Matrix vesicle plasma cell membrane glycoprotein-1 regulates mineralization by murine osteoblastic MC3T3 cells. Journal of Bone and Mineral Research 14 883-892
Mahmood I, Green MD, & Fisher JE 2003 Selection of the First-Time Dose in Humans: Comparison of Different Approaches Based on Interspecies Scaling of Clearance. J. Clin. Pharmacol., 43 (7), 692-7
Maniatis, et al. Cold Springs Harbor Laboratory (1989)
Meyer 1984
Meyer, J.L. 1984 Can biological calcification occur in the presence of pyrophosphate? Arch Biochem Biophys 231 1-8
Millán 1995
Millán 2006
Millán, J.L. 2006 Mammalian Alkaline Phosphatases. From Biology to Applications in Medicine and Biotechnology, Wiley-VCH Verlag GmbH & Co., Weinheim, Germany 1-322
Morris et al. 1992
Morris, D.C., Masuhara, K., Takaoka, K., Ono, K. & Anderson, H.C. 1992 Immunolocalization of alkaline phosphatase in osteoblasts and matrix vesicles of human fetal bone. Bone Miner 19 287-98
Murshed M, Harmey D, Millan JL, McKee MD & Karsenty G 2005 Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes and Development 19 1093-1104
N. Engl. J. Med. 321: 574
Narisawa et al. 1997
Narisawa et al. 2001
Narisawa et al., 1997
Narisawa S, Frohlander N & Millan JL 1997 Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Developmental Dynamics 208 432-446
Narisawa S, Wennberg C & Millan JL 2001 Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. Journal of Pathology 193 125-133
Nasu et al.
Nasu et al. 2006
Nasu M, Ito M, Ishida Y, Numa N, Komaru K, Nomura S and Oda K 2006 Aberrant interchain disulfide bridge of tissue-nonspecific alkalinephosphatase with an Arg433. Cys substitution associated with severe hypophosphatasia FEBS Journal 273 5612-5624
Nishioka et al. 2006
Nosjean et al., 1997
Oda et al., J. Biochem 126: 694-699, 1999
Rezende et al. 1998
Saudek et al., 1989
Smolen und Ball, Controlled Drug Bioavailability, Drug product design und performance, 1984, John Wiley & Sons; Ranade und Hollinger, Drug Delivery Systems, pharmacology und toxicology series, 2003, 2. Auflage, CRRC Press
Urlaub et al., 1983, erhalten von Dr. Lawrence A. Chasin, Columbia University
Waymire et al. 1995
Waymire et al., 1995
Weiss et al. 1988
Weninger et al. 1989
Whyte 1994
Whyte 2001
Whyte et al. 1982
Whyte et al. 1984
Whyte et al. 2003
Whyte et al., 1985
Whyte, 1995
Whyte, 2001
Zurutuza et al 1999
Zurutuza et al. 1999

Also Published As

Publication number Publication date
LU92976I2 (en) 2016-04-11
FR16C0007I2 (fr) 2017-01-27
DK2662448T3 (en) 2017-03-20
ES2380546T3 (es) 2012-05-16
BRPI0811198A2 (pt) 2014-10-21
AU2008250945A2 (en) 2009-12-24
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
FR16C0007I1 (https=) 2016-04-15
LTPA2016004I1 (lt) 2016-02-25
DK2368999T3 (da) 2014-05-26
CY2016005I2 (el) 2016-08-31
EP2158319A1 (en) 2010-03-03
EP2158319A4 (en) 2010-07-21
NL300798I1 (https=) 2016-03-16
AU2008250945B2 (en) 2013-12-12
JP5732603B2 (ja) 2015-06-10
BR122019000505A2 (pt) 2021-12-14
EP2368999A1 (en) 2011-09-28
PL2368999T3 (pl) 2014-08-29
HRP20140416T1 (hr) 2014-06-20
WO2008138131A9 (en) 2009-08-06
PT2662448T (pt) 2017-03-29
PL2158319T3 (pl) 2012-05-31
NO2016002I2 (no) 2016-02-02
CY2016005I1 (el) 2016-08-31
PL2662448T3 (pl) 2017-07-31
HK1141047A1 (en) 2010-10-29
ME01828B (me) 2014-12-20
SI2662448T1 (sl) 2017-05-31
BR122019000505B1 (pt) 2022-01-18
JP2010526543A (ja) 2010-08-05
PL2158319T4 (pl) 2016-04-29
NL300798I2 (https=) 2016-03-16
LTC2368999I2 (lt) 2017-09-25
HK1191372A1 (en) 2014-07-25
DK2158319T3 (da) 2012-03-19
PT2158319E (pt) 2012-03-06
AU2008250945A1 (en) 2008-11-20
NO2016002I1 (no) 2016-02-02
CA2687001C (en) 2019-02-12
EP2158319B1 (en) 2011-12-07
HUS1600005I1 (hu) 2016-02-29
RS53302B (sr) 2014-08-29
SI2368999T1 (sl) 2014-07-31
IL202057A0 (en) 2011-08-01
BRPI0811198B8 (pt) 2021-05-25
ES2619332T3 (es) 2017-06-26
ATE536413T1 (de) 2011-12-15
US20100297119A1 (en) 2010-11-25
BRPI0811198A8 (pt) 2018-08-14
BRPI0811198B1 (pt) 2021-03-09
HK1162589A1 (en) 2012-08-31
WO2008138131A1 (en) 2008-11-20
PT2368999E (pt) 2014-05-26
ES2471915T3 (es) 2014-06-27
EP2662448B1 (en) 2016-12-21
EP2368999B1 (en) 2014-03-12
WO2008138131A4 (en) 2008-12-31
CA2687001A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
DE202008018131U1 (de) Auf Knochen gezielte alkalische Phosphatase und Kits davon
DE69636621T2 (de) Verwendung von chimären proteinen im transport von ausgewählten substanten in die zelle
AU2005209360B2 (en) Production and purification of recombinant arylsulfatase A
US11702642B2 (en) Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
KR20160117487A (ko) 키메라 알칼리성 포스파타제-유사 단백질
KR20170095278A (ko) 재조합 알칼리성 포스파타제를 이용한 발작 치료
EP2675472A1 (en) Methods for treating lysosomal acid lipase deficiency
JP2020015733A (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
JP2024506912A (ja) アルカリホスファターゼポリペプチド及びその使用方法
AU2013203875A1 (en) Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof
HK1162589B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1141047B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1191372B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof

Legal Events

Date Code Title Description
R150 Utility model maintained after payment of first maintenance fee after three years
R207 Utility model specification

Effective date: 20120223

R082 Change of representative

Representative=s name: PATENTANWAELTE ISENBRUCK BOESL HOERSCHLER LLP, 816

Representative=s name: PATENTANWAELTE ISENBRUCK BOESL HOERSCHLER LLP, DE

R081 Change of applicant/patentee

Owner name: ALEXION PHARMA HOLDING, IE

Free format text: FORMER OWNER: ENOBIA PHARMA INC., MONTREAL, CA

Effective date: 20120305

Owner name: ALEXION PHARMA HOLDING, IE

Free format text: FORMER OWNER: ENOBIA PHARMA INC., MONTREAL, QUEBEC, CA

Effective date: 20120305

Owner name: ALEXION PHARMACEUTICALS, INC., 06410 CHESHIRE, US

Free format text: FORMER OWNER: ENOBIA PHARMA INC., MONTREAL, QUEBEC, CA

Effective date: 20120305

Owner name: ALEXION PHARMA INTERNATIONAL SARL, CH

Free format text: FORMER OWNER: ENOBIA PHARMA INC., MONTREAL, CA

Effective date: 20120305

R082 Change of representative

Representative=s name: PATENTANWAELTE ISENBRUCK BOESL HOERSCHLER LLP, DE

Effective date: 20120305

R081 Change of applicant/patentee

Owner name: ALEXION PHARMA HOLDING, IE

Free format text: FORMER OWNER: ENOBIA CANADA LIMITED PARTNERSHIP, MONTREAL, CA

Effective date: 20130328

Owner name: ALEXION PHARMA HOLDING, IE

Free format text: FORMER OWNER: ENOBIA CANADA LIMITED PARTNERSHIP, MONTREAL, QUEBEC, CA

Effective date: 20130328

Owner name: ALEXION PHARMACEUTICALS, INC., 06410 CHESHIRE, US

Free format text: FORMER OWNER: ENOBIA CANADA LIMITED PARTNERSHIP, MONTREAL, QUEBEC, CA

Effective date: 20130328

Owner name: ALEXION PHARMA INTERNATIONAL SARL, CH

Free format text: FORMER OWNER: ENOBIA CANADA LIMITED PARTNERSHIP, MONTREAL, CA

Effective date: 20130328

R082 Change of representative

Representative=s name: PATENTANWAELTE ISENBRUCK BOESL HOERSCHLER LLP, DE

Effective date: 20130328

R081 Change of applicant/patentee

Owner name: ALEXION PHARMA HOLDING, IE

Free format text: FORMER OWNER: ALEXION PHARMA INTERNATIONAL SARL, LAUSANNE, CH

Effective date: 20131016

Owner name: ALEXION PHARMACEUTICALS, INC., 06410 CHESHIRE, US

Free format text: FORMER OWNER: ALEXION PHARMA INTERNATIONAL SARL, LAUSANNE, CH

Effective date: 20131016

R082 Change of representative

Representative=s name: PATENTANWAELTE ISENBRUCK BOESL HOERSCHLER LLP, DE

Effective date: 20131016

R151 Utility model maintained after payment of second maintenance fee after six years

Effective date: 20140618

R081 Change of applicant/patentee

Owner name: ALEXION PHARMACEUTICALS, INC., 06410 CHESHIRE, US

Free format text: FORMER OWNER: ALEXION PHARMA HOLDING, HAMILTON, IE

R082 Change of representative

Representative=s name: PATENTANWAELTE ISENBRUCK BOESL HOERSCHLER LLP, DE

R152 Utility model maintained after payment of third maintenance fee after eight years
R071 Expiry of right